Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifapentine and Isoniazid in Children With Latent Tuberculosis Infection
NCT03730181Phase 2Completed
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Nov 2019
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rifapentine in Tuberculosis (TB), sponsored by Centers for Disease Control and Prevention. Primary endpoint: Rifapentine Pharmacokinetic Exposure at 12 weeks. Started Nov 2019; status: completed.
02
Drugs
rifapentine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03730181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03730181.